Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Farma de Colombia SA
Sponsor:
Information provided by (Responsible Party):
Farma de Colombia SA
ClinicalTrials.gov Identifier:
NCT01850160
First received: May 7, 2013
Last updated: May 9, 2013
Last verified: May 2013

May 7, 2013
May 9, 2013
April 2013
April 2014   (final data collection date for primary outcome measure)
Safety and Efficacy of the fixed-dose combination treatment with Valsartan plus Chlorthalidone [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Efficacy and safety of a fixed-dose combination treatment of Valsartan plus Chlorthalidone Vs Valsartan or Chlorthalidone alone in the treatment of patients with arterial hypertension
Same as current
Complete list of historical versions of study NCT01850160 on ClinicalTrials.gov Archive Site
  • Changes in Systolic and Diastolic Blood pressure values [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Assess the changes in Systolic and Diastolic Blood Pressure from baseline up to week 12
  • Changes of Systolic blood pressure values [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Assess the changes of systolic blood pressure from baseline up to week 6 and 12
  • Changes of Diastolic blood pressure values [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Assess the changes of diastolic blood pressure from baseline up to week 6 and 12
  • Changes of diastolic blood pressure in arterial blood pressure median values [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Assess the changes in diastolic blood pressure in Arterial Blood Pressure Media from baseline up to week 12
  • Changes of systolic blood pressure values in arterial blood pressure median values [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Assess the change in systolic blood pressure in Arterial Blood Pressure Median from baseline up to week 12
  • Patient that achieving blood pressure values lower than 140/90 (systolic/diastolic) at week 6 and 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Determine the percentage of patients achieving blood pressure values lower than 140/90 (systolic/diastolic) at weeks 6 and 12
  • Patients that achieving systolic blood pressure values lower than 140 at week 6 and 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Determine the percentage of patients achieving systolic blood pressure lower than 140 at weeks 6 and 12
  • Patients that achieving diastolic blood pressure values lower than 90 at week 6 and 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Determine the percentage of patients achieving diastolic blood pressure lower than 90 at week 6 and 12
Changes in Systolic and Diastolic Blood pressure [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Changes in Systolic and Diastolic Blood Pressure from baseline up to week 12
  • Metabolic changes secondary to the treatment with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Identify if there are significant differences regarding metabolic changes secondary to the treatment with Valsartan and Chlorthalidone Vs Valsartan or Chlorthalidone.
  • Incidence of adverse events in each intervention group [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Determine the percentage of incidence of adverse events in each intervention group.
  • Change of Systolic blood pressure [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Change in systolic blood pressure from baseline up to week 6 and 12
  • Change of Diastolic blood pressure [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Change in diastolic blood pressure from baseline up to week 6 and 12
  • Patients with systolic blood Pressure lower than 140 mmHg [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Determinate the percentage of patients achieving Systolic blood pressure lower than 140 mmHg at week 6 and 12
  • Patients with Diastolic blood pressure lower than 90 mmHg [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Determinate the percentage of patients achieving Diastolic blood pressure lower than 90 mmHg at week 6 and 12
  • Metabolic changes secondary to the treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Measure the significant differences related with metabolic changes secondary to the treatment with Valsartan and Chlorthalidone Vs Valsartan or Chlorthalidone
  • Incidence rate of adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Determinate the incidence events in each intervention group
 
Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension
Efficacy and Safety of the Fixed-dose Combination of Valsartan Plus Chlorthalidone Vs Valsartan or Chlorthalidone Alone in the Treatment of Arterial Hypertension, Open-label, Controlled, Randomized and Multicenter Trial

This trial is aimed to assess the efficacy and safety of a fixed-dose combination therapy with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone alone for treatment of adult patients with diagnosis of arterial hypertension.

In spite of the existence of a great variety of treatments with drugs effective against arterial hypertension, the percentages of arterial hypertension control with monotherapy remain quite low reason why the fixed-dose combinations of drugs have been one of the most interesting research topics in order to achieve an appropriate control of arterial hypertension.

The possibility of achieving better coverage and Blood Pressure control through a drug combination has leaded, on a scientific base of the efficacy of an Angiotensin Receptor Blockers II plus diuretic combination, to the development of a great number of combinations with different Angiotensin II Receptor Blockers plus hydrochlorothiazide. Yet it is noteworthy that despite the increasing evidence showing additional benefits in Blood pressure control and reduction of cardiovascular outcomes with chlorthalidone over hydrochlorothiazide, there is neither a great number of combinations nor studies with Angiotensin II Receptor Blockers plus chlorthalidone whereby the conduction of a trial assessing the efficacy and safety of Valsartan plus chlorthalidone in hypertensive patients is proposed plus the benefits of combination therapy that include, among others, the greater efficacy with lower doses of each individual component as well as reduction in occurrence of adverse events directly related with lower drug doses.With this treatment schedule it is expected to obtain higher control of blood pressure values and greater percentage of patients.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Hypertension
  • Drug: GROUP A: Valsartan plus Chlorthalidone
    Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
    Other Names:
    • Chlorthalidone Drug Combination
    • Valsartan Drug Combination
    • Antihypertensive Agents
  • Drug: GROUP B: Valsartan
    GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
    Other Names:
    • Angiotensin II Receptor Antagonist
    • Antihypertensive Agents
  • Drug: GROUP C: Chlorthalidone
    GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
    Other Names:
    • Sodium Chloride Symporter Inhibitors
    • Antihypertensive Agents
    • Diuretics
  • Experimental: GROUP A: Valsartan plus Chlorthalidone
    GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
    Intervention: Drug: GROUP A: Valsartan plus Chlorthalidone
  • Experimental: GROUP B: Valsartan
    GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
    Intervention: Drug: GROUP B: Valsartan
  • Experimental: GROUP C: Chlorthalidone
    GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
    Intervention: Drug: GROUP C: Chlorthalidone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
124
April 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient with diagnosis of arterial hypertension defined as:
  • Systolic blood pressure greater or equal to 140 and lower than 180 mmHg
  • Diastolic blood pressure greater or equal to 90 and lower than 110 mmHg
  • Non controlled patients with antihypertensive treatment (blood pressure values: Systolic blood pressure > 140 mmHg and/or Diastolic blood pressure > 90 mmHg) or patients antihypertensive treatment-naïve.
  • Likelihood of attending consultations according to the trial chronogram.
  • Informed Consent Signature.

Exclusion Criteria:

  • Diagnosis of severe or malignant arterial hypertension defined as:
  • Systolic blood pressure greater or equal to 180 mmHg
  • Diastolic blood pressure greater or equal to 110 mmHg
  • Patients with secondary arterial hypertension of any etiology.
  • Pregnant women or women with childbearing potential who are not using appropriate contraception methods; women planning to become pregnant during the trial.
  • Patients with history of Acute Myocardial Infarction o Angina Pectoris within the 6 months prior to the trial initiation.
  • Diagnosis of Cerebrovascular Disease (CVD) o Transient Ischemic Attack (TIA) within the 6 previous months.
  • Patients with Severe Renal Disease defined by serum Creatinine levels higher than 1.5 mg/dl.
  • Diagnosed or suspected unilateral or bilateral renal artery stenosis.
  • History of non remitting cancer within the 5 years prior to the trial initiation.
  • Patients with Hypokalemia or Hyperkalemia.
  • Patients receiving Valsartan or Chlortalidone during the 14 previous days.
  • Patients with known hypersensitivity to Valsartan or Chlorthalidone.
  • Unstable patients with antecedent of hospitalization within the 4 days prior to their enrollment in the trial.
  • Patients with history of drugs and alcohol abuse within the last year.
  • Patients who have taken part in other clinical trial within the 4 weeks prior to the initiation of this research.
  • Patients with any other clinical condition that the investigator deems may affect the patient follow-up.
Both
18 Years to 70 Years
No
Colombia,   Ecuador
 
NCT01850160
005-12 HTA
No
Farma de Colombia SA
Farma de Colombia SA
Not Provided
Study Director: Juan D Romero, MD Farma de Colombia SA
Farma de Colombia SA
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP